LAPTM4B and hepatocellular carcinoma: Moreover, AP4 regulates LAPTM4B, and activates the PI3K/AKT signaling pathway and glycogen synthase kinase 3 beta (GSK3b), leading to c-myc accumulation, which amplified the effect of the PI3K/AKT pathway on the drug resistance of hepatocellular carcinoma cells (27).